{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:41:07Z","timestamp":1793407267457,"version":"4.5.0"},"reference-count":350,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100010218","name":"Department of Science and Technology","doi-asserted-by":"publisher","award":["SR\/FST\/LSI434\/2010"],"award-info":[{"award-number":["SR\/FST\/LSI434\/2010"]}],"id":[{"id":"10.13039\/501100010218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007341","name":"Chhattisgarh Council of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001427","name":"All India Council for Technical Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001427","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006940","name":"University of Mississippi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006940","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.jconrel.2018.05.011","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T05:39:42Z","timestamp":1527140382000},"page":"139-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":605,"special_numbering":"C","title":["Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs"],"prefix":"10.1016","volume":"281","author":[{"given":"Mukta","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0368-5917","authenticated-orcid":false,"given":"Swarnlata","family":"Saraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra","family":"Saraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia G.","family":"Antimisiaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahavir Bhupal","family":"Chougule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunday A.","family":"Shoyele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0391-7650","authenticated-orcid":false,"given":"Amit","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2018.05.011_bb0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2016.11.025","article-title":"Nanotechnology-based drug delivery systems for Alzheimer's disease management: technical, industrial, and clinical challenges","volume":"245","author":"Wen","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0010","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12603-014-0515-3","article-title":"Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies","volume":"19","author":"Lista","year":"2015","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0015","first-page":"332","article-title":"Alzheimer's & dementia","volume":"11","author":"2015 Alzheimer's disease facts and figures","year":"2015","journal-title":"J. Alzheimer's Assoc."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1155\/2016\/8501693","article-title":"Current research therapeutic strategies for Alzheimer\u2019s disease treatment","volume":"2016","author":"Folch","year":"2016","journal-title":"Neural Plast."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0025","doi-asserted-by":"crossref","first-page":"847","DOI":"10.4161\/hv.28183","article-title":"Vaccination against Alzheimer disease: an update on future strategies","volume":"10","author":"Fettelschoss","year":"2014","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0030","series-title":"World Alzheimer Report 2016, London","first-page":"140","article-title":"Improving healthcare for people living with dementia","author":"Prince","year":"2016"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0035","series-title":"Alzheimer's & Dementia","first-page":"325","volume":"vol. 13","author":"2017 Alzheimer's disease facts and figures","year":"2017"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0040","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1742-7843.2010.00664.x","article-title":"Modulation of H2O2-induced mitogen-activated protein kinases activation and cell death in SK-N-MC cells by EUK134, a salen derivative","volume":"108","author":"Mohammadi","year":"2011","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0045","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1517\/17425247.2011.561311","article-title":"Drug delivery strategies for Alzheimer's disease treatment","volume":"8","author":"Di Stefano","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0050","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1021\/nn300489k","article-title":"PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer's disease","volume":"6","author":"Brambilla","year":"2012","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0055","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jocn.2003.12.007","article-title":"Alzheimer's disease pathogenesis and therapeutic interventions","volume":"11","author":"Parihar","year":"2004","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0060","doi-asserted-by":"crossref","DOI":"10.1080\/17425247.2018.1471058","article-title":"Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region","author":"Agrawal","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0065","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1517\/17425247.2013.762354","article-title":"Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB","volume":"10","author":"Nagpal","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pharmthera.2004.08.001","article-title":"Delivery of therapeutic agents to the central nervous system: the problems and the possibilities","volume":"104","author":"Begley","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0075","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.pneurobio.2008.12.002","article-title":"Delivery of peptide and protein drugs over the blood-brain barrier","volume":"87","author":"Brasnjevic","year":"2009","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0080","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1517\/17425247.3.3.419","article-title":"Drug delivery across the blood\u2013brain barrier: why is it difficult? How to measure and improve it?","volume":"3","author":"Su","year":"2006","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0085","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jconrel.2017.05.019","article-title":"Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease","volume":"260","author":"Agrawal","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0090","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/jcbfm.2014.215","article-title":"Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration","volume":"35","author":"Lochhead","year":"2015","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0095","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2217\/fmb.12.1","article-title":"Defense at the border: the blood-brain barrier versus bacterial foreigners","volume":"7","author":"van Sorge","year":"2012","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000321044","article-title":"Nasal drug delivery in humans","volume":"40","author":"Bitter","year":"2011","journal-title":"Curr. Probl. Dermatol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0105","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1517\/17425247.2011.566267","article-title":"Intranasal delivery of stem cells to the brain","volume":"8","author":"Jiang","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0110","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s11095-012-0915-1","article-title":"Intranasal treatment of central nervous system dysfunction in humans","volume":"30","author":"Chapman","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0115","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/10717549709051878","article-title":"Delivery of 125I-NGF to the brain via the olfactory route","volume":"4","author":"Frey","year":"1997","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/JAD-1998-1102","article-title":"Delivery of nerve growth factor to the brain via the olfactory pathway","volume":"1","author":"Chen","year":"1998","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0125","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejcb.2009.02.001","article-title":"Intranasal delivery of cells to the brain","volume":"88","author":"Danielyan","year":"2009","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/rej.2010.1130","article-title":"Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease","volume":"14","author":"Danielyan","year":"2011","journal-title":"Rejuvenation Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/156720511794604598","article-title":"Modulation of anxiety behavior by intranasally administered vaccinia virus complement control protein and curcumin in a mouse model of Alzheimer's disease","volume":"8","author":"Kulkarni","year":"2011","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0169-409X(97)00060-4","article-title":"Intranasal drug delivery","volume":"29","author":"Hussain","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0150","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/1061186X.2013.876644","article-title":"Intranasal therapeutic strategies for management of Alzheimer's disease","volume":"22","author":"Sood","year":"2014","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejpb.2014.03.004","article-title":"Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules","volume":"88","author":"Fortuna","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0160","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2012.03.003","article-title":"Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids","volume":"134","author":"Grassin-Delyle","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/157488507779422374","article-title":"Nasal drug delivery system-factors affecting and applications","volume":"2","author":"Kisan","year":"2007","journal-title":"Curr. Drug Ther."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0170","series-title":"Neurologic Agents for Nasal Administration to the Brain","author":"II","year":"1991"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0175","series-title":"Methods, Pharmaceutical Composition and Articles of Manufacture for Administering Therapeutic Cells to the Animal Central Nervous System","author":"Frey","year":"2012"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0180","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1023\/B:PHAM.0000026431.55383.69","article-title":"Uptake of melatonin into the cerebrospinal fluid after nasal and intravenous delivery: studies in rats and comparison with a human study","volume":"21","author":"van den Berg","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0185","doi-asserted-by":"crossref","DOI":"10.1208\/pt030105","article-title":"Targeted brain delivery of 17 beta-estradiol via nasally administered water soluble prodrugs","volume":"3","author":"Al-Ghananeem","year":"2002","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0190","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0195","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.3109\/10717544.2016.1153748","article-title":"Pharmacological, toxicological and neuronal localization assessment of galantamine\/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer's disease management","volume":"23","author":"Hanafy","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0200","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3109\/03639045.2015.1062897","article-title":"Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain","volume":"41","author":"Hanafy","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/JAD-142421","article-title":"Nasal application of the Galantamine pro-drug Memogain slows down plaque deposition and ameliorates behavior in 5X familial Alzheimer's disease mice","volume":"46","author":"Bhattacharya","year":"2015","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0210","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.etap.2012.04.012","article-title":"Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes","volume":"34","author":"Li","year":"2012","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0215","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijpharm.2013.05.009","article-title":"Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration","volume":"452","author":"Yang","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0220","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejps.2012.04.013","article-title":"Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting","volume":"47","author":"Fazil","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0225","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1016\/j.biomaterials.2013.02.003","article-title":"Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration","volume":"34","author":"Liu","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0230","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1177\/0269881113494939","article-title":"Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Abeta(2)(5)(\u2212)(3)(5) non-transgenic mouse model of Alzheimer's disease","volume":"27","author":"Maurice","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0235","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijpharm.2011.12.008","article-title":"Enhancement of nose-to-brain delivery of basic fibroblast growth factor for improving rat memory impairments induced by co-injection of beta-amyloid and ibotenic acid into the bilateral hippocampus","volume":"423","author":"Feng","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0240","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijpharm.2013.11.049","article-title":"Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease","volume":"461","author":"Zhang","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0245","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jconrel.2007.05.026","article-title":"Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration","volume":"121","author":"Gao","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0250","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.biomaterials.2015.11.057","article-title":"Ionizing radiation-engineered nanogels as insulin nanocarriers for the development of a new strategy for the treatment of Alzheimer's disease","volume":"80","author":"Picone","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0255","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.expneurol.2014.06.004","article-title":"Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Abeta level and microglia activation in the brains of 3xTg-AD mice","volume":"261","author":"Chen","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0260","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/acel.12498","article-title":"Intranasal insulin alleviates cognitive deficits and amyloid pathology in young adult APPswe\/PS1dE9 mice","volume":"15","author":"Mao","year":"2016","journal-title":"Aging Cell"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0265","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3233\/JAD-150307","article-title":"Central nervous system delivery of intranasal insulin: mechanisms of uptake and effects on cognition","volume":"47","author":"Salameh","year":"2015","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0270","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0275","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ejpb.2011.10.012","article-title":"A novel small Odorranalectin-bearing cubosomes: preparation, brain delivery and pharmacodynamic study on amyloid-beta(2)(5)(\u2212)(3)(5)-treated rats following intranasal administration","volume":"80","author":"Wu","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0280","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2014.04.015","article-title":"Development, characterization and application of in situ gel systems for intranasal delivery of tacrine","volume":"468","author":"Qian","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0285","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ijbiomac.2014.03.022","article-title":"Donepezil nanosuspension intended for nose to brain targeting: in vitro and in vivo safety evaluation","volume":"67","author":"Bhavna","year":"2014","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0290","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/IJN.S151474","article-title":"Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease","volume":"13","author":"Meng","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0295","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/npp.2010.245","article-title":"Huperzine A activates Wnt\/beta-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model","volume":"36","author":"Wang","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0300","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijpharm.2008.03.029","article-title":"Intranasal nanoemulsion based brain targeting drug delivery system of risperidone","volume":"358","author":"Kumar","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0305","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1002\/jps.24557","article-title":"Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer's disease: optimization, biological efficacy, and potential toxicity","volume":"104","author":"Elnaggar","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0310","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3233\/JAD-151024","article-title":"Intranasal Administration of a Polyethylenimine-Conjugated Scavenger Peptide Reduces Amyloid-beta Accumulation in a mouse model of Alzheimer's disease","volume":"53","author":"Lin","year":"2016","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0315","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.neurobiolaging.2012.05.009","article-title":"Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease","volume":"34","author":"Guo","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0320","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.neulet.2014.11.013","article-title":"Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP\/PS1 model of amyloid accumulation","volume":"584","author":"Fine","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0325","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s13346-011-0050-2","article-title":"Intranasal delivery of deferoxamine reduces spatial memory loss in APP\/PS1 mice","volume":"2","author":"Hanson","year":"2012","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0330","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fnagi.2015.00104","article-title":"Intranasal deferoxamine attenuates synapse loss via up-regulating the P38\/HIF-1alpha pathway on the brain of APP\/PS1 transgenic mice","volume":"7","author":"Guo","year":"2015","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0335","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejps.2016.05.012","article-title":"Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer's disease","volume":"92","author":"Muntimadugu","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0340","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1007\/s11095-015-1744-9","article-title":"Intranasal H102 peptide-loaded liposomes for brain delivery to treat Alzheimer's disease","volume":"32","author":"Zheng","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0345","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.npep.2014.04.005","article-title":"Enhancement of the nonamyloidogenic pathway by exogenous NGF in an Alzheimer transgenic mouse model","volume":"48","author":"Yang","year":"2014","journal-title":"Neuropeptides"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/97b6c799-1ebc-4e7b-8f86-47c1130dc00e","article-title":"Intranasal \"painless\" human nerve growth factor [corrected] slows amyloid neurodegeneration and prevents memory deficits in app X PS1 mice","volume":"7","author":"Capsoni","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0355","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3233\/JAD-2009-0953","article-title":"Delivery of NGF to the brain: intranasal versus ocular administration in anti-NGF transgenic mice","volume":"16","author":"Capsoni","year":"2009","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0360","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1073\/pnas.0500195102","article-title":"Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice","volume":"102","author":"De Rosa","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0365","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3233\/JAD-160355","article-title":"Development of nasal lipid nanocarriers containing curcumin for brain targeting","volume":"59","author":"Vaz","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0370","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/jphp.12043","article-title":"Enhanced brain targeting of curcumin by intranasal administration of a thermosensitive poloxamer hydrogel","volume":"65","author":"Chen","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0375","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3109\/1061186X.2012.719230","article-title":"Formulation and evaluation of microemulsion-based in situ ion-sensitive gelling systems for intranasal administration of curcumin","volume":"20","author":"Wang","year":"2012","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0380","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ijpharm.2016.09.042","article-title":"Phytochemical-loaded mesoporous silica nanoparticles for nose-to-brain olfactory drug delivery","volume":"513","author":"Lungare","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0385","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3109\/10717544.2015.1092619","article-title":"Development of an optimized hyaluronic acid-based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery","volume":"23","author":"Nasr","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0390","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0395","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0169-409X(97)00059-8","article-title":"Nasal mucociliary clearance as a factor in nasal drug delivery","volume":"29","author":"Merkus","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0400","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/jps.20480","article-title":"Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting","volume":"95","author":"Vyas","year":"2006","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2018.05.011_bb0405","first-page":"40","article-title":"Intranasal drug delivery bypasses the blood\u2013brain barrier","volume":"24","author":"William","year":"2016","journal-title":"Neurol. Rev."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0410","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1530\/rep.1.00278","article-title":"Counter-current transfer in reproductive biology","volume":"129","author":"Einer-Jensen","year":"2005","journal-title":"Reproduction (Cambridge, England)"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","article-title":"Transport of drugs from the nasal cavity to the central nervous system","volume":"11","author":"Illum","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0420","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00688493","article-title":"Uptake of exogenous proteins in mouse olfactory cells","volume":"19","author":"Kristensson","year":"1971","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0425","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2012.09.017","article-title":"Approaches for breaking the barriers of drug permeation through transdermal drug delivery","volume":"164","author":"Alexander","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0430","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1012029517394","article-title":"The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual","volume":"14","author":"Florence","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/DDC-120001481","article-title":"Nanoparticle technology for drug delivery across the blood-brain barrier","volume":"28","author":"Lockman","year":"2002","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0440","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1211\/0022357011775145","article-title":"The biopharmaceutical aspects of nasal mucoadhesive drug delivery","volume":"53","author":"Ugwoke","year":"2001","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0445","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","article-title":"Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies","volume":"270","author":"Pires","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0450","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/archotol.134.6.643","article-title":"Intranasal administration of drugs","volume":"134","author":"Scheibe","year":"2008","journal-title":"Arch. Otolaryngol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0455","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/01.MLG.0000199741.08517.99","article-title":"Breath actuated device improves delivery to target sites beyond the nasal valve","volume":"116","author":"Djupesland","year":"2006","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0460","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-2008-13309","article-title":"Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults","volume":"13","author":"Reger","year":"2008","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0465","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/10611860310001640075","article-title":"Hydroxocobalamin uptake into the cerebrospinal fluid after nasal and intravenous delivery in rats and humans","volume":"11","author":"Van den Berg","year":"2003","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0470","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1080\/10611860802476504","article-title":"Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting","volume":"16","author":"Kumar","year":"2008","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0475","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2016.09.017","article-title":"Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives","volume":"241","author":"Alexander","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089454","article-title":"Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease","volume":"9","author":"Bhattacharya","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0485","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1016\/j.bmc.2015.07.058","article-title":"Galantamine derivatives with indole moiety: docking, design, synthesis and acetylcholinesterase inhibitory activity","volume":"23","author":"Atanasova","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"Suppl A","key":"10.1016\/j.jconrel.2018.05.011_bb0490","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1016\/S0149-2918(01)80164-8","article-title":"Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine","volume":"23","author":"Farlow","year":"2001","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0495","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bbr.2009.12.044","article-title":"The history of the cholinergic hypothesis","volume":"221","author":"Contestabile","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0500","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/11591860-000000000-00000","article-title":"Combination therapy for Alzheimer's disease","volume":"28","author":"Patel","year":"2011","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0505","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuro.2007.11.004","article-title":"Antioxidative properties of galantamine on neuronal damage induced by hydrogen peroxide in SK-N-SH cells","volume":"29","author":"Ezoulin","year":"2008","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0510","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pbb.2006.08.007","article-title":"Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval","volume":"85","author":"de Bruin","year":"2006","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0515","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1211\/jpp.58.2.0002","article-title":"Skin permeation of retinol in tween 20-based deformable liposomes: in-vitro evaluation in human skin and keratinocyte models","volume":"58","author":"Oh","year":"2006","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0520","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jns.2009.01.024","article-title":"Galantamine inhibits beta-amyloid aggregation and cytotoxicity","volume":"280","author":"Matharu","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0525","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.molbrainres.2004.08.010","article-title":"Galantamine blocks cloned Kv2.1, but not Kv1.5 potassium channels, brain research","volume":"131","author":"Zhang","year":"2004","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0530","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2011.11.010","article-title":"Modern methods for delivery of drugs across the blood\u2013brain barrier","volume":"64","author":"Chen","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0535","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/10717544.2013.849778","article-title":"Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation","volume":"21","author":"Galgatte","year":"2014","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0540","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3109\/10717544.2014.880860","article-title":"Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease","volume":"22","author":"Bhatt","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0545","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3109\/10717544.2013.860501","article-title":"Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization","volume":"22","author":"Ravi","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0550","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jfda.2014.10.008","article-title":"Impact of chitosan composites and chitosan nanoparticle composites on various drug delivery systems: a review","volume":"23","author":"Elgadir","year":"2015","journal-title":"J. Food Drug Anal."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0555","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.2174\/0929867321666140716103130","article-title":"Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders","volume":"21","author":"Ong","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0560","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.yrtph.2009.09.015","article-title":"The safety of chitosan as a pharmaceutical excipient","volume":"56","author":"Baldrick","year":"2010","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0565","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2217\/nnm.12.87","article-title":"Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system","volume":"7","author":"Bamrungsap","year":"2012","journal-title":"Nanomedicine (London, England)"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0570","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3109\/03639045.2015.1011167","article-title":"A comparative study of chitosan and poloxamer based thermosensitive hydrogel for the delivery of PEGylated melphalan conjugates","volume":"41","author":"Alexander","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0575","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/jphp.12262","article-title":"Formulation and evaluation of chitosan-based long-acting injectable hydrogel for PEGylated melphalan conjugate","volume":"66","author":"Alexander","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0580","first-page":"217","article-title":"Kinetic modeling on drug release from controlled drug delivery systems","volume":"67","author":"Dash","year":"2010","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0585","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12031-009-9269-5","article-title":"Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy","volume":"40","author":"Maelicke","year":"2010","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0590","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF03349887","article-title":"Nasal spray vs oral administration of bromocriptine: pharmacology and effect on serum prolactin in puerperal women","volume":"19","author":"Cicinelli","year":"1996","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0595","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","article-title":"Therapeutics of Alzheimer's disease: past, present and future","volume":"76","author":"Anand","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0600","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.03.025","article-title":"Intranasal delivery: physicochemical and therapeutic aspects","volume":"337","author":"Costantino","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0605","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0168-3659(99)00222-9","article-title":"Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties","volume":"65","author":"Touitou","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0610","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/S0142-9612(01)00052-7","article-title":"Intracellular delivery mediated by an ethosomal carrier","volume":"22","author":"Touitou","year":"2001","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0615","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijpharm.2006.05.027","article-title":"Deformable liposomes and ethosomes: mechanism of enhanced skin delivery","volume":"322","author":"Elsayed","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0620","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neuroscience.2005.08.063","article-title":"Galantamine increases excitability of CA1 hippocampal pyramidal neurons","volume":"137","author":"Oh","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0625","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.biomaterials.2004.02.020","article-title":"Effect of edge activators on the formation and transfection efficiency of ultradeformable liposomes","volume":"26","author":"Lee","year":"2005","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0630","first-page":"133","article-title":"Deformable liposomes and ethosomes as carriers for skin delivery of ketotifen","volume":"62","author":"Elsayed","year":"2007","journal-title":"Die Pharmazie"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0635","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1081\/DDC-120025458","article-title":"Transfersomes\u2014a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation","volume":"29","author":"Jain","year":"2003","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0640","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.regpep.2007.06.012","article-title":"Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders","volume":"149","author":"Hallschmid","year":"2008","journal-title":"Regul. Pept."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0645","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1389557513666131119201353","article-title":"Donepezil: an important prototype to the design of new drug candidates for Alzheimer's disease","volume":"14","author":"Rodrigues Simoes","year":"2014","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0650","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0301-0082(97)00028-2","article-title":"The cholinergic system in Alzheimer's disease","volume":"52","author":"K\u00e1sa","year":"1997","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0655","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40262-013-0038-9","article-title":"Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease","volume":"52","author":"Noetzli","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0660","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1023\/A:1012128907225","article-title":"Chitosan and chitosan\/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines","volume":"14","author":"Calvo","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0665","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2165\/00002512-199813050-00005","article-title":"Rivastigmine. A review of its use in Alzheimer's disease","volume":"13","author":"Spencer","year":"1998","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0670","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jalz.2006.03.002","article-title":"Aggressive course of disease in dementia","volume":"2","author":"Gauthier","year":"2006","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0675","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1212\/01.wnl.0000281846.40390.50","article-title":"Pharmacokinetic rationale for the rivastigmine patch","volume":"69","author":"Cummings","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0680","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pnpbp.2004.10.006","article-title":"Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients","volume":"29","author":"Tenovuo","year":"2005","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0685","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1185\/030079906X162791","article-title":"Strategies to improve tolerability of rivastigmine: a case series","volume":"23","author":"Venkatesh","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0690","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144337","article-title":"Adverse effects of cholinesterase inhibitors in dementia, according to the Pharmacovigilance databases of the United-States and Canada","volume":"10","author":"Ali","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0695","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3390\/ph3040961","article-title":"Cell-penetrating peptides-mechanisms of cellular uptake and generation of delivery systems","volume":"3","author":"Trabulo","year":"2010","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0700","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1021\/mp800121f","article-title":"Endocytosis and membrane potential are required for HeLa cell uptake of R.I.-CKTat9, a retro-inverso tat cell penetrating peptide","volume":"6","author":"Zhang","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0705","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ijpharm.2011.08.001","article-title":"Distinct transduction modes of arginine-rich cell-penetrating peptides for cargo delivery into tumor cells","volume":"419","author":"Ma","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0710","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.addr.2007.10.008","article-title":"Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers","volume":"60","author":"Torchilin","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0715","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0168-3659(01)00486-2","article-title":"Design of biodegradable particles for protein delivery","volume":"78","author":"Vila","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0720","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijpharm.2005.03.027","article-title":"Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor","volume":"298","author":"Akta\u015f","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0725","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0168-3659(87)90035-6","article-title":"A simple equation for description of solute release II. Fickian and anomalous release from swellable devices","volume":"5","author":"Ritger","year":"1987","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0730","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1189\/jlb.0904541","article-title":"Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration","volume":"78","author":"Porporatto","year":"2005","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0735","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0168-3659(95)00146-8","article-title":"The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro","volume":"39","author":"Borchard","year":"1996","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0740","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2007.05.022","article-title":"Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123","volume":"122","author":"Tosi","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0745","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.nano.2009.02.005","article-title":"Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution","volume":"5","author":"Vergoni","year":"2009","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0750","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1358\/mf.2005.27.3.890872","article-title":"Actions of tacrine and galanthamine on histamine-N-methyltransferase","volume":"27","author":"Taraschenko","year":"2005","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0755","series-title":"Drugs@FDA: FDA Approved Drug Products","article-title":"Drug database","author":"FDA","year":"2018"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0760","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF00315027","article-title":"Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine","volume":"38","author":"Hartvig","year":"1990","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0765","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00003088-199528060-00003","article-title":"Clinical pharmacokinetics of tacrine","volume":"28","author":"Madden","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0770","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ageing\/20.2.129","article-title":"Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer's disease","volume":"20","author":"O'Brien","year":"1991","journal-title":"Age Ageing"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0775","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1001\/jama.280.20.1777","article-title":"Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' collaboration","volume":"280","author":"Qizilbash","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0780","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2174\/138920008784220619","article-title":"Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer's disease","volume":"9","author":"Patocka","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0785","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1007\/s11095-010-0127-5","article-title":"Intranasal delivery\u2014modification of drug metabolism and brain disposition","volume":"27","author":"Wong","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0790","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/WAD.0b013e318157205b","article-title":"Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting","volume":"22","author":"Jogani","year":"2008","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0795","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1124\/jpet.301.1.391","article-title":"Intranasal delivery of morphine","volume":"301","author":"Illum","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0800","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1517\/17425240902939135","article-title":"PecSys: in situ gelling system for optimised nasal drug delivery","volume":"6","author":"Watts","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0805","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0168-3659(00)00341-2","article-title":"Understanding drug release from poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) gels","volume":"70","author":"Anderson","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0810","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0169-409X(01)00242-3","article-title":"Thermosensitive sol-gel reversible hydrogels","volume":"54","author":"Jeong","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0815","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1517\/17425247.2011.581656","article-title":"Thermosensitive hydrogels for drug delivery","volume":"8","author":"Li","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0820","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ejpb.2014.07.005","article-title":"Saraf, polyethylene glycol (PEG)-poly(N-isopropylacrylamide) (PNIPAAm) based thermosensitive injectable hydrogels for biomedical applications","volume":"88","author":"Alexander","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0825","first-page":"339","article-title":"Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations","volume":"9","author":"Escobar-Chavez","year":"2006","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0830","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ejpb.2004.03.019","article-title":"In situ-forming hydrogels\u2014review of temperature-sensitive systems","volume":"58","author":"Ruel-Gariepy","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0835","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0378-5173(86)90182-1","article-title":"Drug release from Pluronic F-127 gels","volume":"32","author":"Gilbert","year":"1986","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0840","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/j.2042-7158.2011.01315.x","article-title":"In-situ gel formulations of econazole nitrate: preparation and in-vitro and in-vivo evaluation","volume":"63","author":"Baloglu","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0845","first-page":"88","article-title":"In situ mucoadhesive nasal gels of metoclopramide hydrochloride: preformulation and formulation studies","volume":"1","author":"Jitendra","year":"2008","journal-title":"J. Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0850","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1208\/s12249-012-9893-1","article-title":"Thermoreversible nasal in situ gel of venlafaxine hydrochloride: formulation, characterization, and pharmacodynamic evaluation","volume":"14","author":"Bhandwalkar","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0855","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0378-5173(99)00227-6","article-title":"Development of a thermo-reversible insulin liquid suppository with bioavailability enhancement","volume":"189","author":"Yun","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0860","first-page":"711","article-title":"Nasal Mucoadhesive in situ gel of ondansetron hydrochloride","volume":"71","author":"Bhalerao","year":"2009","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0865","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3109\/03639040903264371","article-title":"Preparation of nasal temperature-sensitive in situ gel of Radix Bupleuri and evaluation of the febrile response mechanism","volume":"36","author":"Chen","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"7","key":"10.1016\/j.jconrel.2018.05.011_bb0870","first-page":"67","article-title":"Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan","author":"Majithiya","year":"2006","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0875","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0168-3659(00)00215-7","article-title":"Experimental investigation and mathematical modeling of Pluronic F127 gel dissolution: drug release in stirred systems","volume":"67","author":"Moore","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0880","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jps.22314","article-title":"Poloxamer\/cyclodextrin\/chitosan-based thermoreversible gel for intranasal delivery of fexofenadine hydrochloride","volume":"100","author":"Cho","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0885","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pedhc.2011.02.008","article-title":"Efficacy of Risperidone in managing maladaptive behaviors for children with autistic Spectrum disorder: a meta-analysis","volume":"26","author":"Sharma","year":"2012","journal-title":"J. Pediatr. Health Care"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0890","series-title":"Risperdal Prescribing Information Label","year":"2014"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0895","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/1567201053586047","article-title":"Intranasal drug delivery for brain targeting","volume":"2","author":"Vyas","year":"2005","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0900","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/10611869808997870","article-title":"Nasal route for direct delivery of solutes to the central nervous system: fact or fiction?","volume":"5","author":"Mathison","year":"1998","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0905","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1021\/js9900295","article-title":"Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats","volume":"88","author":"Chow","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0910","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijpharm.2004.01.039","article-title":"Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain","volume":"275","author":"Zhang","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0915","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0920","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/416535a","article-title":"Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo","volume":"416","author":"Walsh","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0925","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0166-2236(03)00067-5","article-title":"The metallobiology of Alzheimer's disease","volume":"26","author":"Bush","year":"2003","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0930","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-510X(98)00092-6","article-title":"Copper, iron and zinc in Alzheimer's disease senile plaques","volume":"158","author":"Lovell","year":"1998","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0935","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.neurobiolaging.2007.10.012","article-title":"Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid","volume":"30","author":"Strozyk","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0940","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neurobiolaging.2008.02.018","article-title":"Altered expression and distribution of zinc transporters in APP\/PS1 transgenic mouse brain","volume":"31","author":"Zhang","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0945","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-0173(03)00174-7","article-title":"Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta","volume":"43","author":"Atwood","year":"2003","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0950","doi-asserted-by":"crossref","first-page":"7939","DOI":"10.1021\/bi900907a","article-title":"Ternary complexes of iron, amyloid-beta, and nitrilotriacetic acid: binding affinities, redox properties, and relevance to iron-induced oxidative stress in Alzheimer's disease","volume":"48","author":"Jiang","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0955","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/978-1-60327-029-8_25","article-title":"Detection and localization of markers of oxidative stress by in situ methods: application in the study of Alzheimer disease","volume":"610","author":"Moreira","year":"2010","journal-title":"Methods Mol. Biol. (Clifton, N.J.)"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0960","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.arr.2004.01.002","article-title":"Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease","volume":"3","author":"Castellani","year":"2004","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0965","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3233\/JAD-2004-6610","article-title":"Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3","volume":"6","author":"Lovell","year":"2004","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0970","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0002-9343(00)00547-7","article-title":"Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease","volume":"109","author":"Pratico","year":"2000","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0975","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2174\/0929867013372922","article-title":"Chemistry and biochemistry of oxidative stress in neurodegenerative disease","volume":"8","author":"Sayre","year":"2001","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0980","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0896-6273(01)00317-8","article-title":"Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice","volume":"30","author":"Cherny","year":"2001","journal-title":"Neuron"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0985","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/0140-6736(91)92978-B","article-title":"Intramuscular desferrioxamine in patients with Alzheimer's disease","volume":"337","author":"Crapper McLachlan","year":"1991","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jconrel.2018.05.011_bb0990","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.spen.2006.08.008","article-title":"Iron: a new target for pharmacological intervention in neurodegenerative diseases","volume":"13","author":"Whitnall","year":"2006","journal-title":"Semin. Pediatr. Neurol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb0995","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3233\/JAD-2004-6310","article-title":"Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease","volume":"6","author":"House","year":"2004","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1000","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1385\/JMN:24:1:129","article-title":"FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein","volume":"24","author":"Morse","year":"2004","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/156720507781788927","article-title":"Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG","volume":"4","author":"Avramovich-Tirosh","year":"2007","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1010","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1749-6632.2000.tb06938.x","article-title":"Metal chelation as a potential therapy for Alzheimer's disease","volume":"920","author":"Cuajungco","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1015","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0300-483X(88)90010-8","article-title":"Neurotoxicity associated with deferoxamine therapy","volume":"49","author":"Freedman","year":"1988","journal-title":"Toxicology"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1020","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ijc.2910630421","article-title":"Influence of hepatic artery occlusion and desferrioxamine on liver-tumour growth","volume":"63","author":"Lindner","year":"1995","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1025","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.neuropharm.2003.09.005","article-title":"Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats","volume":"46","author":"Shachar","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1030","series-title":"Prog. Med. Chem","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0079-6468(08)70220-0","article-title":"5 the present status of chelating agents in medicine","author":"May","year":"1983"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1035","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/jpet.108.149807","article-title":"Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke","volume":"330","author":"Hanson","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1040","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1126\/science.2111583","article-title":"Cleavage of amyloid beta peptide during constitutive processing of its precursor","volume":"248","author":"Esch","year":"1990","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.brainres.2004.02.081","article-title":"Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain","volume":"1012","author":"Arendash","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1050","doi-asserted-by":"crossref","first-page":"864","DOI":"10.2174\/156720512802455386","article-title":"Roles of glycogen synthase kinase 3 in Alzheimer's disease","volume":"9","author":"Cai","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1055","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1007\/s00018-007-7218-4","article-title":"Causes of oxidative stress in Alzheimer disease","volume":"64","author":"Zhu","year":"2007","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1060","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.neuint.2010.03.025","article-title":"Long-chain 3-hydroxy fatty acids accumulating in LCHAD and MTP deficiencies induce oxidative stress in rat brain","volume":"56","author":"Tonin","year":"2010","journal-title":"Neurochem. Int."},{"issue":"10","key":"10.1016\/j.jconrel.2018.05.011_bb1065","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3233\/JAD-2006-102-315","article-title":"Aluminum and other metals in Alzheimer's disease: a review of potential therapy with chelating agents","author":"Domingo","year":"2006","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1741-7015-7-7","article-title":"Recent developments in Alzheimer's disease therapeutics","volume":"7","author":"Rafii","year":"2009","journal-title":"BMC Med."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1075","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","article-title":"Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial","volume":"7","author":"Wilcock","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1080","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1172\/JCI18162","article-title":"NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo","volume":"112","author":"Eriksen","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1085","series-title":"Phase 3 Trial of Flurizan\u2122 in Alzheimer's Disease","author":"Myriad Genetics Reports Results of U.S.","year":"2008"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1090","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1095","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3233\/JAD-2009-1092","article-title":"Why did tarenflurbil fail in Alzheimer's disease?","volume":"17","author":"Imbimbo","year":"2009","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1100","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijpharm.2015.03.065","article-title":"Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting","volume":"486","author":"Swami","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1105","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/j.biomaterials.2004.07.050","article-title":"Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs","volume":"26","author":"Win","year":"2005","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1110","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jconrel.2010.11.033","article-title":"Neurotherapeutic applications of nanoparticles in Alzheimer's disease","volume":"152","author":"Sahni","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1115","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1166\/jbn.2012.1380","article-title":"Poly(ethylene glycol) hydroxystearate-based nanosized emulsions: effect of surfactant concentration on their formation and ability to solubilize quercetin","volume":"8","author":"Dora","year":"2012","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1120","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1023\/A:1016121319668","article-title":"A novel phase inversion-based process for the preparation of lipid nanocarriers","volume":"19","author":"Heurtault","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1125","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0887-2333(03)00145-0","article-title":"Progressing toward the reduction, refinement and replacement of laboratory animal procedures: thoughts on some encounters with Dr Iain purchase","volume":"18","author":"Balls","year":"2004","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1130","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ejpb.2008.10.009","article-title":"Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue","volume":"72","author":"Horvat","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1135","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2011.09.083","article-title":"Administration of resveratrol: what formulation solutions to bioavailability limitations?","volume":"158","author":"Amri","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2011.02.040","article-title":"Poly(ethylene oxide\/propylene oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal zidovudine delivery to the brain","volume":"411","author":"Ved","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1145","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jconrel.2013.10.006","article-title":"Poly(ethylene glycol)-poly(lactic-co-glycolic acid) based thermosensitive injectable hydrogels for biomedical applications","volume":"172","author":"Alexander","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1150","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1474-9726.2011.00724.x","article-title":"Insulin-activated Akt rescues Abeta oxidative stress-induced cell death by orchestrating molecular trafficking","volume":"10","author":"Picone","year":"2011","journal-title":"Aging Cell"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1155","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1096\/fj.06-7703com","article-title":"Amyloid beta oligomers induce impairment of neuronal insulin receptors","volume":"22","author":"Zhao","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1160","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1155\/2010\/147835","article-title":"Insulin promotes survival of amyloid-beta oligomers Neuroblastoma damaged cells via Caspase 9 inhibition and Hsp70 Upregulation","volume":"2010","author":"Di Carlo","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1165","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3233\/JAD-2012-111880","article-title":"Impaired neuronal insulin signaling precedes Abeta42 accumulation in female AbetaPPsw\/PS1DeltaE9 mice","volume":"29","author":"Chua","year":"2012","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1170","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.psyneuen.2004.04.003","article-title":"Intranasal insulin improves memory in humans","volume":"29","author":"Benedict","year":"2004","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1175","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejphar.2004.02.040","article-title":"The source of cerebral insulin","volume":"490","author":"Banks","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1180","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0149-7634(00)00040-3","article-title":"Insulin receptors and insulin action in the brain: review and clinical implications","volume":"24","author":"Schulingkamp","year":"2000","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1185","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1021\/nn1008319","article-title":"Multifunctional hybrid nanogel for integration of optical glucose sensing and self-regulated insulin release at physiological pH","volume":"4","author":"Wu","year":"2010","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1190","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1166\/jnn.2015.9865","article-title":"Radiation-engineered functional nanoparticles in aqueous systems","volume":"15","author":"Dispenza","year":"2015","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2017.11.040","article-title":"Nose-to-brain delivery of insulin enhanced by a nanogel carrier","volume":"270","author":"Picone","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1200","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2165\/00003088-200140120-00003","article-title":"Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations","volume":"40","author":"Thorne","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1205","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/jps.20318","article-title":"Nasal drug administration: potential for targeted central nervous system delivery","volume":"94","author":"Graff","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1210","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0378-5173(03)00039-5","article-title":"Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats","volume":"255","author":"Dufes","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1215","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s10059-000-0142-1","article-title":"In vivo gene transfer to the mouse nasal cavity mucosa using a stable cationic lipid emulsion","volume":"10","author":"Kim","year":"2000","journal-title":"Mol. Cells"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1220","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.molmed.2004.01.001","article-title":"Unravelling the role of Humanin","volume":"10","author":"Nishimoto","year":"2004","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1225","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1385\/MN:30:3:327","article-title":"Humanin: after the discovery","volume":"30","author":"Niikura","year":"2004","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1230","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/sj.bjp.0704429","article-title":"[Gly(14)]-Humanin improved the learning and memory impairment induced by scopolamine in vivo","volume":"134","author":"Mamiya","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1235","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/jnr.20391","article-title":"A humanin derivative, S14G-HN, prevents amyloid-beta-induced memory impairment in mice","volume":"79","author":"Tajima","year":"2005","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1240","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1248\/bpb.30.350","article-title":"Cubosomes: an overview","volume":"30","author":"Garg","year":"2007","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1245","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1074\/mcp.M600334-MCP200","article-title":"Anti-infection peptidomics of amphibian skin","volume":"6","author":"Li","year":"2007","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002381","article-title":"Odorranalectin is a small peptide lectin with potential for drug delivery and targeting","volume":"3","author":"Li","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1255","first-page":"471","article-title":"Olfactory epithelium of the rat. Lectin-mediated histochemical studies","volume":"25","author":"Melgarejo Moreno","year":"1998","journal-title":"An. Otorrinolaringol. Iberoam."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1260","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF01002469","article-title":"Lectin-binding pattern of neuroepithelial and respiratory epithelial cells in the mouse nasal cavity","volume":"21","author":"Lundh","year":"1989","journal-title":"Histochem. J."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1265","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1021\/la010161w","article-title":"Novel process for producing cubic liquid crystalline nanoparticles (Cubosomes)","volume":"17","author":"Spicer","year":"2001","journal-title":"Langmuir"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1270","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijpharm.2006.12.029","article-title":"Huperzine a in rat plasma and CSF following intranasal administration","volume":"337","author":"Yue","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1275","first-page":"1104","article-title":"Preparation of huperzine A nasal in situ gel and evaluation of its brain targeting following intranasal administration","volume":"41","author":"Tao","year":"2006","journal-title":"Yao xue xue bao"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1280","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1745-7254.2007.00486.x","article-title":"Drug brain distribution following intranasal administration of Huperzine a in situ gel in rats","volume":"28","author":"Zhao","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1285","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1091\/mbc.e06-10-0975","article-title":"Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils","volume":"18","author":"Majumdar","year":"2007","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1290","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0197-4580(02)00237-3","article-title":"Microglial overexpression of the M-CSF receptor augments phagocytosis of opsonized Abeta","volume":"24","author":"Mitrasinovic","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1295","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0304-3940(03)00474-9","article-title":"Macrophage colony stimulating factor promotes phagocytosis by murine microglia","volume":"344","author":"Mitrasinovic","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1300","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.neuro.2005.01.016","article-title":"Erythropoietin: a novel neuroprotective cytokine","volume":"26","author":"Bartesaghi","year":"2005","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1305","first-page":"263","article-title":"Brain protection by erythropoietin: a manifold task","volume":"23","author":"Rabie","year":"2008","journal-title":"Physiology (Bethesda, MD)"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1310","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.nbd.2006.10.009","article-title":"Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus","volume":"25","author":"Nadam","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1315","doi-asserted-by":"crossref","first-page":"9848","DOI":"10.1073\/pnas.0901840106","article-title":"Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons","volume":"106","author":"Sanchez","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1320","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/nen.0b013e3180517b28","article-title":"Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment","volume":"66","author":"Assaraf","year":"2007","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1325","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1111\/j.1471-4159.2006.03697.x","article-title":"Erythropoietin reduces perihematomal inflammation and cell death with eNOS and STAT3 activations in experimental intracerebral hemorrhage","volume":"96","author":"Lee","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1330","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/00004647-199906000-00007","article-title":"A potential role for erythropoietin in focal permanent cerebral ischemia in mice","volume":"19","author":"Bernaudin","year":"1999","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1335","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1073\/pnas.95.8.4635","article-title":"In vivo evidence that erythropoietin protects neurons from ischemic damage","volume":"95","author":"Sakanaka","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1340","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1073\/pnas.042693799","article-title":"Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury","volume":"99","author":"Celik","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1345","doi-asserted-by":"crossref","first-page":"10526","DOI":"10.1073\/pnas.97.19.10526","article-title":"Erythropoietin crosses the blood\u2013brain barrier to protect against experimental brain injury","volume":"97","author":"Brines","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1350","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ana.20274","article-title":"Beneficial effect of erythropoietin on experimental allergic encephalomyelitis","volume":"56","author":"Li","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1355","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bbr.2003.11.002","article-title":"Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rats","volume":"153","author":"Kumral","year":"2004","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1360","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.expneurol.2006.11.002","article-title":"Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model","volume":"204","author":"Grunfeld","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1365","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2174\/156720205774962683","article-title":"Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity","volume":"2","author":"Chong","year":"2005","journal-title":"Curr. Neurovasc. Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1370","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.neuropharm.2009.02.006","article-title":"Erythropoietin protects PC12 cells from beta-amyloid(25-35)-induced apoptosis via PI3K\/Akt signaling pathway","volume":"56","author":"Ma","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1375","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1100\/tsw.2009.103","article-title":"The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans","volume":"9","author":"Garcia-Rodriguez","year":"2009","journal-title":"TheScientificWorldJOURNAL"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1380","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0006-8993(95)01032-7","article-title":"Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction","volume":"706","author":"Maurice","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1385","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.addr.2003.10.030","article-title":"Lectin-mediated drug targeting: history and applications","volume":"56","author":"Bies","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1390","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.169.3951.1217","article-title":"Polypeptide with broad biological activity: isolation from small intestine","volume":"169","author":"Said","year":"1970","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1395","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1073\/pnas.78.10.6535","article-title":"Vasoactive intestinal polypeptide induces glycogenolysis in mouse cortical slices: a possible regulatory mechanism for the local control of energy metabolism","volume":"78","author":"Magistretti","year":"1981","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1400","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF02740671","article-title":"VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment","volume":"10","author":"Muller","year":"1995","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1405","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1749-6632.1998.tb11180.x","article-title":"VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide","volume":"865","author":"Brenneman","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1410","doi-asserted-by":"crossref","first-page":"10883","DOI":"10.1523\/JNEUROSCI.2594-09.2009","article-title":"NGF is essential for hippocampal plasticity and learning","volume":"29","author":"Conner","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1415","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1523\/JNEUROSCI.6314-11.2012","article-title":"TrkA gene ablation in basal forebrain results in dysfunction of the cholinergic circuitry","volume":"32","author":"Sanchez-Ortiz","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1420","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jchemneu.2011.02.004","article-title":"Gender differences in neurotrophin and glutamate receptor expression in cholinergic nucleus basalis neurons during the progression of Alzheimer's disease","volume":"42","author":"Counts","year":"2011","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1425","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1073\/pnas.83.19.7537","article-title":"Basic fibroblast growth factor supports the survival of cerebral cortical neurons in primary culture","volume":"83","author":"Morrison","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1430","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0006-8993(94)91188-6","article-title":"Characterization of basic fibroblast growth factor-mediated acceleration of axonal branching in cultured rat hippocampal neurons","volume":"661","author":"Aoyagi","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1435","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1460-9568.1990.tb00009.x","article-title":"Fibroblast growth factor enhances long-term potentiation in the hippocampal slice","volume":"Vol. 2","author":"Terlau","year":"1990","journal-title":"Eur. J. Neurosc."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1440","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.expneurol.2008.11.011","article-title":"Basic fibroblast growth factor-enhanced neurogenesis contributes to cognitive recovery in rats following traumatic brain injury","volume":"216","author":"Sun","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1445","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI16618","article-title":"FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice","volume":"112","author":"Yoshimura","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1450","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.1073\/pnas.94.15.8179","article-title":"Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebralinfarction","volume":"94","author":"Kawamata","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1455","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1073858410371513","article-title":"Expression and functions of fibroblast growth factor 2 (FGF-2) in hippocampal formation","volume":"16","author":"Zechel","year":"2010","journal-title":"Neuroscientist"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1460","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/0006-291X(90)91201-3","article-title":"Basic fibroblast growth factor in Alzheimer's disease","volume":"171","author":"Stopa","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1465","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1152\/physrev.1997.77.4.1081","article-title":"Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives","volume":"77","author":"Mattson","year":"1997","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1470","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0022-510X(96)05335-X","article-title":"Altered apolipoprotein E secretion in cytokine treated human astrocyte cultures","volume":"148","author":"Baskin","year":"1997","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1475","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0169-328X(99)00186-2","article-title":"Roles of p53, c-Myc, Bcl-2, Bax and caspases in glutamate-induced neuronal apoptosis and the possible neuroprotective mechanism of basic fibroblast growth factor, brain research","volume":"71","author":"Liu","year":"1999","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1480","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery\u2014possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1485","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10719-008-9119-7","article-title":"Lectins as tools in glycoconjugate research","volume":"26","author":"Wu","year":"2009","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1490","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.addr.2003.10.015","article-title":"The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery","volume":"56","author":"Gabor","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1495","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/BF01460825","article-title":"Histochemical study of glycoconjugates in the nasal mucosa of the rat and Guinea pig","volume":"24","author":"Pastor","year":"1992","journal-title":"Histochem. J."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1500","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0141-8130(01)00131-3","article-title":"Myo-inositol hexasulphate and low molecular weight heparin binding to human acidic fibroblast growth factor: a calorimetric and FTIR study","volume":"28","author":"Guzman-Casado","year":"2001","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1505","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1016\/S0021-9258(17)41730-3","article-title":"Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding","volume":"269","author":"Roghani","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1510","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/cbic.200700338","article-title":"Branched KLVFF tetramers strongly potentiate inhibition of beta-amyloid aggregation","volume":"8","author":"Chafekar","year":"2007","journal-title":"Chembiochem"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1515","doi-asserted-by":"crossref","first-page":"7882","DOI":"10.1021\/bi002734u","article-title":"Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF","volume":"40","author":"Lowe","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1520","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1021\/bi982824n","article-title":"Modified-peptide inhibitors of amyloid beta-peptide polymerization","volume":"38","author":"Findeis","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1525","doi-asserted-by":"crossref","first-page":"8545","DOI":"10.1074\/jbc.271.15.8545","article-title":"Arrest of beta-amyloid fibril formation by a pentapeptide ligand","volume":"271","author":"Tjernberg","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1530","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm0798-822","article-title":"Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy","volume":"4","author":"Soto","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1535","doi-asserted-by":"crossref","first-page":"13905","DOI":"10.1074\/jbc.M211976200","article-title":"Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease","volume":"278","author":"Adessi","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1540","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.jmb.2008.11.009","article-title":"A new amyloid-like beta-aggregate with amyloid characteristics, except fibril morphology","volume":"385","author":"Chang","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1545","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharmthera.2005.03.010","article-title":"Metabolism of amyloid-beta peptide and Alzheimer's disease","volume":"108","author":"Iwata","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1550","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1021\/cn100057j","article-title":"Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's disease transgenic mice","volume":"1","author":"Aileen Funke","year":"2010","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1555","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1096\/fj.01-0841fje","article-title":"Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide","volume":"16","author":"Permanne","year":"2002","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1560","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/cbic.200300631","article-title":"Selection of D-amino-acid peptides that bind to Alzheimer's disease amyloid peptide abeta1-42 by mirror image phage display","volume":"4","author":"Wiesehan","year":"2003","journal-title":"Chembiochem"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1565","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/anie.200802123","article-title":"Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies","volume":"48","author":"Frydman-Marom","year":"2009","journal-title":"Angew. Chem."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1570","article-title":"Feasibility of beta-sheet breaker peptide-H102 treatment for Alzheimer's disease based on beta-amyloid hypothesis","volume":"9","author":"Lin","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1575","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000106378","article-title":"Intranasal insulin to improve memory function in humans","volume":"86","author":"Benedict","year":"2007","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1580","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.neuroimage.2011.01.062","article-title":"Fast and robust extraction of hippocampus from MR images for diagnostics of Alzheimer's disease","volume":"56","author":"Lotjonen","year":"2011","journal-title":"NeuroImage"},{"issue":"Suppl. 3","key":"10.1016\/j.jconrel.2018.05.011_bb1585","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2202-9-S3-S5","article-title":"Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease","volume":"9","author":"Hanson","year":"2008","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1590","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0006-8993(95)00637-6","article-title":"Quantitative analysis of the olfactory pathway for drug delivery to the brain","volume":"692","author":"Thorne","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1595","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1211\/0022357022539","article-title":"Is nose-to-brain transport of drugs in man a reality?","volume":"56","author":"Illum","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1600","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.2174\/138161210791164108","article-title":"Potential of nanoparticulate drug delivery systems by intranasal administration","volume":"16","author":"Ali","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1605","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/smll.200901158","article-title":"Effect of surface properties on nanoparticle-cell interactions","volume":"6","author":"Verma","year":"2010","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1610","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1385\/JMN:20:3:315","article-title":"From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division","volume":"20","author":"Gozes","year":"2003","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1615","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1385\/JMN:24:1:067","article-title":"NAP mechanisms of neuroprotection","volume":"24","author":"Gozes","year":"2004","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1620","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1527-3458.2005.tb00053.x","article-title":"NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP)","volume":"11","author":"Gozes","year":"2005","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1625","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1046\/j.1471-4159.1999.0721283.x","article-title":"Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide","volume":"72","author":"Bassan","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1630","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0167-0115(00)00198-1","article-title":"A novel peptide prevents death in enriched neuronal cultures","volume":"96","author":"Zemlyak","year":"2000","journal-title":"Regul. Pept."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1635","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-3565(24)29662-2","article-title":"A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice","volume":"296","author":"Beni-Adani","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1640","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0005-2736(99)00108-X","article-title":"Cellular internalization of PCL(20)-b-PEO(44) block copolymer micelles","volume":"1421","author":"Allen","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1645","first-page":"798","volume":"48","author":"Chonpathompikunlert","year":"2010","journal-title":"Br. Ind. Biol. Res. Assoc."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1650","first-page":"1","article-title":"Local and systemic safety of intranasal corticosteroids","volume":"22","author":"Sastre","year":"2012","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1655","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1023\/A:1018901302450","article-title":"Chitosan as a novel nasal delivery system for peptide drugs","volume":"11","author":"Illum","year":"1994","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1660","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1002\/jps.24557","article-title":"Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer's disease: optimization, biological efficacy, and potential toxicity","volume":"104","author":"Elnaggar","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1665","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2174\/1567201813666160204114000","article-title":"Understanding the role of Poloxamer 407 based Thermoreversible in situ gelling hydrogel for delivery of PEGylated Melphalan conjugate","volume":"13","author":"Alexander","year":"2016","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1670","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for direct nose-to-brain delivery of drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1675","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ejps.2012.01.002","article-title":"Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration","volume":"45","author":"Zhang","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1680","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.nlm.2010.02.002","article-title":"Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance","volume":"93","author":"McNay","year":"2010","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1685","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12035-011-8229-6","article-title":"Brain insulin signaling and Alzheimer's disease: current evidence and future directions","volume":"46","author":"Schioth","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1690","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.neuron.2008.04.014","article-title":"Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo","volume":"58","author":"Chiu","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1695","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.npp.1301193","article-title":"Intranasal insulin improves memory in humans: superiority of insulin aspart","volume":"32","author":"Benedict","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1700","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/JAD-2005-7107","article-title":"Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease\u2014is this type 3 diabetes?","volume":"7","author":"Steen","year":"2005","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1705","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.exger.2010.08.026","article-title":"Intranasal insulin as a therapeutic option in the treatment of cognitive impairments","volume":"46","author":"Benedict","year":"2011","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1710","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","article-title":"Intranasal insulin improves cognition and modulates beta-amyloid in early AD","volume":"70","author":"Reger","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1715","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1073\/pnas.0809158106","article-title":"Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers","volume":"106","author":"De Felice","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1720","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.neurobiolaging.2007.06.014","article-title":"Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation","volume":"30","author":"Lee","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1725","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40263-013-0076-8","article-title":"Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence","volume":"27","author":"Freiherr","year":"2013","journal-title":"CNS drugs"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1730","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.neurobiolaging.2005.03.016","article-title":"Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype","volume":"27","author":"Reger","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jconrel.2018.05.011_bb1735","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JAD-150040","article-title":"Intranasal delivery of NEMO-binding domain peptide prevents memory loss in a mouse model of Alzheimer's disease","volume":"47","author":"Rangasamy","year":"2015","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1740","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1101\/gad.183434.111","article-title":"NF-kappaB, the first quarter-century: remarkable progress and outstanding questions","volume":"26","author":"Hayden","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1745","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/ni.2065","article-title":"Crosstalk in NF-kappaB signaling pathways","volume":"12","author":"Oeckinghaus","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2018.05.011_bb1750","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1126\/science.289.5484.1550","article-title":"Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex","volume":"289","author":"May","year":"2000","journal-title":"Science (New York, N.Y.)"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918302682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918302682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T14:49:35Z","timestamp":1751640575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365918302682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":350,"alternative-id":["S0168365918302682"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.05.011","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}